Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Phase of Trial: Phase IV
Latest Information Update: 23 Sep 2015
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 23 Sep 2015 New trial record
- 01 Jul 2015 Results published in the American Journal of Hematology.